Company Description
FOXO Technologies Inc. operates as a healthcare services and technology company in the United States.
The company operates through two segments: Healthcare and Labs and Life. The company offers behavioural health; ancillary, including laboratory, radiology, respiratory, and pharmacy; insurance; and other services.
The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging.
It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers.
FOXO Technologies Inc. was founded in 2020 and is based in West Palm Beach, Florida.
| Country | United States |
| Founded | 2019 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 168 |
| CEO | Seamus Lagan |
Contact Details
Address: 477 South Rosemary Ave., Suite 224 West Palm Beach, Florida 33401 United States | |
| Phone | 612-800-0059 |
| Website | foxotechnologies.com |
Stock Details
| Ticker Symbol | FOXO |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001812360 |
| CUSIP Number | 351471305 |
| ISIN Number | US3514713052 |
| Employer ID | 85-1050265 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Seamus Lagan | Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Accounting Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 7, 2025 | DEF 14C | Filing |
| Jun 30, 2025 | 8-K | Current Report |
| Jun 27, 2025 | 8-K | Current Report |
| Jun 26, 2025 | 8-K | Current Report |
| Jun 26, 2025 | PRE 14C | Filing |
| Jun 20, 2025 | D | Notice of Exempt Offering of Securities |
| Jun 17, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 8-K | Current Report |
| Jun 9, 2025 | EFFECT | Notice of Effectiveness |
| Jun 9, 2025 | 424B4 | Prospectus |